Research Progress on Genetic Factors and Hemophilia A Clotting Factor Inhibitor-Review

Hemophilia A (Hemophilia A, HA) is an X-linked recessive hereditary coagulation function disorder, the deficiency and dysfunction of blood coagulation were caused by the mutations of gene encoding clotting factor VIII. The treatment of hemophilia A still depends on the replacement therapy with blood...

Full description

Saved in:
Bibliographic Details
Published inZhongguo shi yan xue ye xue za zhi Vol. 25; no. 3; p. 957
Main Authors Hu, Zheng-Bin, Sun, Xin, He, Li-Ya
Format Journal Article
LanguageChinese
Published China 01.06.2017
Subjects
Blood Coagulation Factors - genetics
Factor VIII
Genetic Therapy
Hemophilia A - genetics
Hemophilia A - therapy
Humans
Mutation
Risk Factors
Online AccessGet more information

Cover

More Information
Summary:Hemophilia A (Hemophilia A, HA) is an X-linked recessive hereditary coagulation function disorder, the deficiency and dysfunction of blood coagulation were caused by the mutations of gene encoding clotting factor VIII. The treatment of hemophilia A still depends on the replacement therapy with blood coagulation factor. However, the repeated infusion of clotting factor will produce the neutralizing antibody against FVIII, then resulting in one of the serious complications. The reports on the incidence of inhibitor are different at home and abroad. Due to diverse factors, the inhibitors of hemophilia A clotting factor mainly can be divided into genetic and environmental factors, In this review, the inhibitors of hemophilia A clotting factor and their risk factors are briefly summarized.
ISSN:1009-2137
DOI:10.7534/j.issn.1009-2137.2017.03.058